Bacterial News and Research

RSS

Study: HIV-specific poison kills persisting HIV-infected cells during antiretroviral therapy

A team including University of North Carolina and NIH scientists has demonstrated in a mouse model that an HIV-specific poison can kill cells in which the virus is actively reproducing despite antiretroviral therapy.

10 Jan 2014

Nottingham scientists use MRI technology to assist in treatment, diagnosis of irritable bowel syndrome

Scientists at The University of Nottingham are leading the world in exploiting MRI technology to assist in the treatment and diagnosis of Irritable Bowel Syndrome (IBS), a condition that causes serious inconvenience and discomfort to sufferers.

10 Jan 2014

Researchers deploy potential new weapon against HIV

Researchers at the UNC School of Medicine have deployed a potential new weapon against HIV - a combination therapy that targets HIV-infected cells that standard therapies cannot kill.

10 Jan 2014

Nottingham scientists exploit MRI technology to assist in the treatment of IBS

Scientists at The University of Nottingham are leading the world in exploiting MRI technology to assist in the treatment and diagnosis of Irritable Bowel Syndrome, a condition that causes serious inconvenience and discomfort to sufferers.

9 Jan 2014

High presence of bacteria linked to early water breaking during pregnancy

A high presence of bacteria at the site where fetal membranes rupture may be the key to understanding why some pregnant women experience their "water breaking" prematurely, researchers at Duke Medicine report.

9 Jan 2014

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Advanced Inhalation Therapies, an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis.

8 Jan 2014

Landes Bioscience releases special issue on sepsis

A special issue on sepsis has been released by the publisher Landes Bioscience (Austin, TX USA). The articles contained in this special issue of the journal Virulence have been authored by world-class investigators and provide new insights into both the pathogen-related factors and the host defense mechanisms that lead to septic shock and contribute to its resolution or fatal outcome.

7 Jan 2014

Low gut microbial diversity in infants' intestines can increase risk for asthma

Low gut microbial diversity in the intestines of infants can increase the risk for asthma development. These are the findings of the age 7 follow-up in a multi-year study led by researchers at Linköping University in Sweden.

7 Jan 2014

Clinical features not sufficiently pathognomonic in pneumonia

Clinical signs and symptoms are not sufficiently reliable to distinguish the different etiologies of pneumonia, Dutch researchers report.

6 Jan 2014

Viewpoints: Stop 'bailout' of Obamacare; health law not to blame for all insurance woes; 'theft' of Medicare advantage money

Shrinking revenues and rising costs could bring on the "death spiral" - an unbalanced patient pool forcing huge premium increases (to restore revenue) that would further unbalance the patient pool as the young and healthy drop out. End result? Insolvency

6 Jan 2014

Uneven distribution of cellular organelles during cell division may enhance bacterial population's survival

Although a population of bacteria may be genetically identical, individual bacteria within that population can act in radically different ways.

3 Jan 2014

Computer algorithm developed to identify genes that could be transformed to stop aging process

Restricting calorie consumption is one of the few proven ways to combat aging. Though the underlying mechanism is unknown, calorie restriction has been shown to prolong lifespan in yeast, worms, flies, monkeys, and, in some studies, humans.

2 Jan 2014

Surgeon highlights factors that can prevent revision surgery after hip or knee replacement

Hundreds of thousands of hip and knee replacement surgeries are performed in the United States each year, and they are highly successful in eliminating pain, restoring mobility and improving quality of life.

2 Jan 2014

Innovative therapy offers new hope to breast cancer patients

A novel breast-cancer therapy that partially reverses the cancerous state in cultured breast tumor cells and prevents cancer development in mice, could one day provide a new way to treat early stages of the disease without resorting to surgery, chemotherapy or radiation, a multi-institutional team led by researchers from the Wyss Institute of Biologically Inspired Engineering at Harvard University reported January 1 in Science Translational Medicine.

2 Jan 2014

Researchers reveal mechanism behind persistent bacteria

The mechanism by which some bacteria are able to survive antibacterial treatment has been revealed for the first time by Hebrew University of Jerusalem researchers. Their work could pave the way for new ways to control such bacteria.

31 Dec 2013

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.

30 Dec 2013

Research could pave way for more effective treatments for bacterial infections

30 Dec 2013

Cancer immunotherapy named 2013 Breakthrough of the Year by journal Science

Detect. Destroy. Remember. The mantra of the immune system's relentless campaign against infectious invaders and the body's own abnormal cells finally is applying to cancer in meaningful ways.

28 Dec 2013

Streptococcus biofilms persist on objects, surfaces in daycare center for longer periods after cleaning

Numerous scientific studies have concluded that two common bacteria that cause colds, ear infections, strep throat and more serious infections cannot live for long outside the human body.

27 Dec 2013

AmpliPhi BioSciences completes sale of $18M of common stock in private placement financing

AmpliPhi BioSciences Corporation, the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has completed the sale of approximately $18 million of common stock in a private placement financing. The Company has issued an aggregate of 72,007,000 shares of the Company's common stock at a price per share of $0.25. Net proceeds from the placement are approximately $16.9 million.

24 Dec 2013

Bacterial News and Research

Study: HIV-specific poison kills persisting HIV-infected cells during antiretroviral therapy

Nottingham scientists use MRI technology to assist in treatment, diagnosis of irritable bowel syndrome

Researchers deploy potential new weapon against HIV

Nottingham scientists exploit MRI technology to assist in the treatment of IBS

High presence of bacteria linked to early water breaking during pregnancy

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Landes Bioscience releases special issue on sepsis

Low gut microbial diversity in infants' intestines can increase risk for asthma

Clinical features not sufficiently pathognomonic in pneumonia

Viewpoints: Stop 'bailout' of Obamacare; health law not to blame for all insurance woes; 'theft' of Medicare advantage money

Uneven distribution of cellular organelles during cell division may enhance bacterial population's survival

Computer algorithm developed to identify genes that could be transformed to stop aging process

Surgeon highlights factors that can prevent revision surgery after hip or knee replacement

Innovative therapy offers new hope to breast cancer patients

Researchers reveal mechanism behind persistent bacteria

FDA accepts Cubist Pharmaceuticals' tedizolid phosphate NDA with Priority Review

Research could pave way for more effective treatments for bacterial infections

Cancer immunotherapy named 2013 Breakthrough of the Year by journal Science

Streptococcus biofilms persist on objects, surfaces in daycare center for longer periods after cleaning

AmpliPhi BioSciences completes sale of $18M of common stock in private placement financing

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News